Agonist activity at recombinant human NMU1 expressed in HEK293 cells assessed as change in intracellular calcium flux at 10 uM by fluorescence assay relative to human NmU
Agonist activity at recombinant human NMU2 expressed in HEK293 cells assessed as change in intracellular calcium flux at 10 uM by fluorescence assay relative to human NmU
Toxicity in DIO C57BL/6 mouse assessed as white blood cells level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 7.35 +/- 1.21 x 10'6/ml)
Toxicity in DIO C57BL/6 mouse assessed as neutrophils level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 1.3 +/- 0.21 x 10'6/ml)
Toxicity in DIO C57BL/6 mouse assessed as lymphocytes level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 4.82 +/- 0.68 x 10'6/ml)
Toxicity in DIO C57BL/6 mouse assessed as monocytes level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 1.07 +/- 0.31 x 10'5/ml)
Toxicity in DIO C57BL/6 mouse assessed as red blood cells level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 9.17 +/- 0.17 x 10'9/ml)
Toxicity in DIO C57BL/6 mouse assessed as platelets level at 2.6 mg/kg, sc administered once a week for 21 days by hematology analyzer (Rvb = 5.97 +/- 0.32 x 10'8/ml)
Antiobesity activity in DIO C57BL/6 mouse assessed as decrease in abdominal fat content at 2.6 mg/kg, sc administered every 2 days for 21 days (Rvb = 8.1 +/- 0.4%)
Antiobesity activity in DIO C57BL/6 mouse assessed as decrease in abdominal fat content at 2.6 mg/kg, sc administered every 4 days for 21 days (Rvb = 8.1 +/- 0.4%)
Antiobesity activity in DIO C57BL/6 mouse assessed as decrease in abdominal fat content at 2.6 mg/kg, sc administered every 7 days for 21 days (Rvb = 8.1 +/- 0.4%)